Avanos Medical, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Vanguard Capital Management has reported beneficial ownership of 5% of Avanos Medical Inc.'s common stock as of June 30, 2026.
NYSE
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 4.3% of Avanos Medical, Inc. common stock as of March 31, 2026.
NYSE
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 3.7% of Avanos Medical Inc.'s common stock as of April 30, 2026.
NYSE
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 11.5% of Avanos Medical Inc.'s common stock as of March 31, 2026.
NYSE
The Vanguard Group has reported a 0% beneficial ownership in Avanos Medical Inc. following an internal realignment, marking a complete divestment of its previously reportable stake.
NYSE
RGM Capital, LLC and Robert G. Moses report 0% beneficial ownership of Avanos Medical, Inc. common stock in their latest Schedule 13G amendment.
NYSE
Dimensional Fund Advisors LP has filed an amendment to its Schedule 13G, disclosing a 4.6% beneficial ownership stake in Avanos Medical Inc. as of December 31, 2025.
NYSE
Armistice Capital, LLC and Steven Boyd have reported a 5.39% beneficial ownership stake in Avanos Medical, Inc., totaling 2,500,000 shares of common stock.
NYSE
The Vanguard Group has disclosed an increased beneficial ownership of 7.38% in Avanos Medical Inc., holding over 3.4 million shares.
NYSE
Dimensional Fund Advisors LP has filed an amended Schedule 13G, disclosing a 5.1% beneficial ownership stake in Avanos Medical Inc.
NYSE
T. Rowe Price Investment Management, Inc. reported a 10.2% beneficial ownership stake in Avanos Medical Inc. common stock as of September 30, 2025.
NYSE
The Vanguard Group has filed an amended Schedule 13G, reporting a 9.65% beneficial ownership stake in Avanos Medical Inc. as of June 30, 2025.
NYSE
SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 8.2% Passive Stake in Avanos Medical Inc.
T. Rowe Price Investment Management, Inc. has disclosed a beneficial ownership of 8.2% of Avanos Medical Inc.'s common stock as of March 31, 2025, held in the ordinary course of business.
NYSE
BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a beneficial ownership of 14.8% in Avanos Medical, Inc. as of March 31, 2025.
NYSE
T. Rowe Price Investment Management, Inc. has reported a 6.6% beneficial ownership stake in Avanos Medical Inc., as detailed in a recent Schedule 13G filing.
NYSE
SCHEDULE 13G/A: RGM Capital, LLC Discloses 6.5% Stake in Avanos Medical, Inc.
RGM Capital, LLC has filed an amended Schedule 13G, reporting a 6.5% beneficial ownership stake in Avanos Medical, Inc. as of December 31, 2024.